Norway· NO-ID_96828C65-0075-4914-9A69-99253FA9953D
RoActemra
A tocilizumab product containing tocilizumab, registered in Norway by Roche Registration GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Tocilizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC L04AC07 (tocilizumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Tocilizumab · ATC L04AC07
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tocilizumab costs, country by country.
Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tocilizumab · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$29.63
The record
At a glance
FEST (Norway)- Active substance
- Tocilizumab
- Manufacturer
- Roche Registration GmbH
- Country
- Norway (NO)
- ATC code
- L04AC07
- ATC class
- Tocilizumab
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 7
3 priced- no_varenummer1700851 x 10NOK 3495.9
- gtin7613326007993
- gtin7613326008006
- gtin7613326007986
- no_merkevare_idID_96828C65-0075-4914-9A69-99253FA9953D
- no_varenummer1701071 x 20NOK 6955.5
- no_varenummer1700621 x 4NOK 1438.3
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
263 interactions on record for tocilizumab.
Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tocilizumab · interactions on record
263 records
- 38 severe
- 218 moderate
- 7 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tocilizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAVTOZMACelltrion Healthcare Hungary Kft., Budapest
- United StatesACTEMRAGenentech, Inc.
- BelgiumAvtozma 20 mg/mlCelltrion Healthcare Hungary
- FinlandAvtozmaCelltrion Healthcare Hungary Kft.
- IrelandAvtozma 20 mg/mL concentrate for solution for infusionCelltrion Healthcare Hungary Kft.
- IcelandAvtozmaCelltrion Healthcare Hungary Kft.
- PolandAvtozmaCelltrion Healthcare Hungary Kft.
- SwedenAvtozma 20 mg/ml Koncentrat till infusionsvätska, lösningCelltrion Healthcare Hungary Kft
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Tofidence
- Iceland · Avtozma, Roactemra
- Liechtenstein · Avtozma, Roactemra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1b749cb-9799-46dd-9304-8ddb4480c7ab GET /v1/drugs/f1b749cb-9799-46dd-9304-8ddb4480c7ab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Tocilizumab",
"merkevare_id": "ID_96828C65-0075-4914-9A69-99253FA9953D",
"name_form_strength": "RoActemra kons til inf oppl 20 mg/ml",
"prescription_group": "C"
}See everything about tocilizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.